Circulating microRNAs as Potential Biomarkers in Glioma: A Mini Review.

Circulating microRNAs as Potential Biomarkers in Glioma: A Mini Review. Endocr Metab Immune Disord Drug Targets. 2020 Jul 30;: Authors: Choppavarapu L, Kandi SM Abstract Glioma comprises of a group of heterogeneous brain tumors originating from glial cells. Primary glioblastoma are among the most common glial cells that have a characteristic clinical and molecular profile. Advancement in the field of cancer research and inventions of various clinical methodologies couldn't improve the median survival of this deadly tumor from 12 months. The development of a non-invasive prognostic biomarker in blood would be a revolution in the diagnosis and therapeutic monitoring of this tumor. Extra cellular vesicles (Evs) are released from the tumor microenvironment into the blood, which contain the genetic material that represents the genetics of tumor cells. It is also seen that these Evs contain a variety of RNA population including miRNAs. Several studies identified that circulating cell free miRNAs, either free or present in Evs, could be considered as a potential biomarker in early diagnosis and prognosis of glioblastoma. Micro RNA studies in glioblastoma have found to be promising, as it reveals the biological pathway behind pathogenesis and helps in predicting the treatment targets. Literature says that various treatment methods change the type and quantity of miRNAs in biological fluids, which can be used to monitor the therapy. This revi...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research